Jan 09, 2023 / 09:30PM GMT
Operator
Greetings, and welcome to the Sutro Biopharma webcast. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to our host, Ed Albini, Chief Financial Officer. Thank you. You may begin.
Edward C. Albini - Sutro Biopharma, Inc. - CFO & Secretary
Thank you, operator. Good afternoon, everyone, and thank you for joining us. With me on the call are Bill Newell, Chief Executive Officer; Dr. Stan Frankel, an esteemed member of our Scientific Advisory Board; Dr. Trevor Hallam, President of Research and Chief Scientific Officer; and Jane Chung, Chief Commercial Officer.
We also welcome on the line Dr. R. Wendel Naumann of the Levine Cancer Institute at Atrium Health. This afternoon, we issued a news release that you can find on our website at www.sutrobio.com, which includes an update from our Phase I Dose-Expansion study of STRO-002, also known as Luveltamab Tazevibuli or luvelta in ovarian cancer as well as our plans moving forward
Sutro Biopharma Inc STRO-002 Update Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers